Efficacy and applications for PuraStat® use in the management of unselected gastrointestinal bleeding: A retrospective observational study

Table 3 Subgroup upper gastrointestinal bleeding (gastroscopy), n = 35, n (%)

Variable	Value
Demographic data
Age (mean ± SD)	65.8 ± 13.7
Gender	Female 15 (42.9)/male 20 (57.1)
Antiplatelet (aspirin 3, clopidogrel 1)	4 (11.4)
Anticoagulant (DOAC 8, warfarin 2, heparin 1)	10 (28.6)
Charlson index score
0	5 (14.3)
1-2	8 (22.9)
3-4	13 (37.1)
≥ 5	9 (25.7)
Transfusion	26 (74.3)
Type of episode
First episode	22 (62.9)
Re-bleeding	12 (34.3)
Second look	1 (2.9)
Biological data (mean ± SD)
BP initial	111 ± 25.5
BP lower 24 hours	103 ± 22.9
HR initial	94.2 ± 22.8
HR higher 24 hours	98.5 ± 22.6
Hb initial	8.5 ± 3.6
Hb lower 24 hours	7.6 ±2.6
Endoscopic data
Type of lesions
Peptic ulcer	15 (42.8)
Neoplasia	6 (17.1)
Peptic oesophagitis	5 (14.3)
Vascular	3 (8.5)
Post polypectomy bleeding	1 (2.9)
Others	5 (14.3)
Ulcer Forrest	Ib 3 (20), Ia 6 (40), IIb 3 (20), IIc1 (6.7), III 2 (13.3)

ERCP: Endoscopic retrograde cholangiopancreatography; BP: Blood pressure; HR: Heart rate; Hb: Haemoglobin; DOAC: Direct oral anti coagulant.